Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Time to abandon microalbuminuria?

P Ruggenenti1, G Remuzzi

  • 1Clinical Research Centre for Rare Diseases 'Aldo e Cele Daccò', Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy.

Kidney International
|July 28, 2006
PubMed
Summary

Albuminuria, even at low levels, indicates increased renal and cardiovascular risk. The distinction between microalbuminuria and macroalbuminuria is less critical than the continuous risk associated with albumin excretion.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetics of rare diseases of the kidney: learning from mouse models.

Cytogenetic and genome research·2004
Same author

Nephrotoxic aspects of cyclosporine.

Transplantation proceedings·2004
Same author

Proteinuria and its consequences in renal disease.

Acta paediatrica (Oslo, Norway : 1992). Supplement·2004
Same author

Pharmacological and clinical profile of valsartan.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

[Thrombotic microangiopathy].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2003
Same author

[Mechanisms of endothelial damage in thrombotic microangiopathy].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2003

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology
  • Metabolic Syndrome Research

Background:

  • Microalbuminuria (urinary albumin excretion [UAE] 20-200 µg/min) identifies increased renal and cardiovascular risk.
  • Risk extends below the microalbuminuric range, down to 2-5 µg/min.
  • Macroalbuminuria (UAE >200 µg/min) signifies proteinuria and progressive disease.

Purpose of the Study:

  • To re-evaluate the clinical significance of albuminuria thresholds.
  • To explore the continuous relationship between albuminuria and disease risk.
  • To propose a shift from traditional micro/macroalbuminuria classifications.

Main Methods:

  • Analysis of urinary albumin excretion (UAE) levels and associated risks.
  • Review of established definitions and clinical implications of albuminuria and proteinuria.
  • Correlation of UAE with metabolic syndrome, insulin resistance, and endothelial dysfunction.

Main Results:

  • A continuous relationship exists between albuminuria levels and renal/cardiovascular risk, with no clear lower threshold distinguishing normal from pathological states.
  • The 200 µg/min threshold effectively separates albuminuria from proteinuria, indicating different risk levels and disease progression.
  • Albuminuria reflects functional abnormalities, while proteinuria indicates established kidney damage.

Conclusions:

  • The terms microalbuminuria and macroalbuminuria may be outdated; 'albuminuria-associated diseases' and 'proteinuria-associated diseases' offer better conceptualization.
  • Risk stratification should consider the continuous nature of albuminuria.
  • Further research is needed to determine optimal therapeutic thresholds for albuminuria.

Related Experiment Videos